Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) were down 49.5% during trading on Wednesday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The firm’s 50-day simple moving average is $2.02 and its two-hundred day simple moving average is $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than H-CYTE
- How to Calculate Return on Investment (ROI)
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- What Do S&P 500 Stocks Tell Investors About the Market?
- How Do Stock Buybacks Affect Shareholders?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.